#USA #San Francisco #Henlius Biotech #Globalisation 2.0 #Innovation Roadmap

Henlius Presents Innovative Strategy at JPM 2026

The 44th J.P. Morgan Healthcare Conference (JPMHC) took place from January 12 to 15, 2026, in San Francisco, gathering leaders from the medical and biopharmaceutical sectors. On January 15, Dr. Jason Zhu, the CEO of Shanghai Henlius Biotech, Inc. (2696.HK), delivered a keynote speech where he introduced the company’s ambitious 'Globalisation 2.0' strategy and a comprehensive innovation roadmap targeting both medium- and long-term development.

Rapid Global Expansion

Henlius has marked significant growth in its international business, aiming to launch over 20 products globally by 2030, with more than 15 of these being targeted at markets in the United States and Europe. Dr. Zhu emphasized the importance of steady growth and the milestones achieved under this innovative strategy.

"With multiple products receiving approvals in both Europe and the U.S., along with our increasingly sophisticated integrated global operation model, we have maintained strong momentum in our international business. Our integrated capabilities in R&D, regulatory approval, and manufacturing bolster our continuously established global network for clinical development and commercialization. This robust framework enables us to consistently deliver innovative drug candidates worldwide," he stated.

Henlius is set to leverage stable cash flows from its biosimilars portfolio over the next five years to fuel further investments in innovation, allowing the company to bring differentiated molecules to market, including Antibody-Drug Conjugates (ADCs), multi-specific antibodies, and T cell engagers (TCEs).

Key Innovations on the Horizon

During the conference, Henlius also unveiled its specific timelines and developmental plans for several important innovation candidates set for 2026. Notable mentions include:

• - Serplulimab (Hetronifly® in Europe): An Anti-PD-1 monoclonal antibody (mAb)
• - HLX22: A novel Epitope Anti-HER2 mAb
• - HLX43: A PD-L1-ADC
• - HLX07: An Anti-EGFR mAb

Currently, Henlius's preclinical portfolio encompasses multiple molecular modalities, including antibodies, multispecific TCEs, ADCs, fusion proteins, and small molecules, with a focus on solid tumors. Their differentiated development strategy targets both established and emerging structures such as PD-(L)1, DLL3, B7-H3, HER2, EGFR, c-Met, and KAT6A/B. The portfolio comprises a balanced mix of potential first-in-class (FIC) and best-in-class (BIC) candidates, along with Fast-Follow programs that promise higher clinical and commercial security.

Strategic Framework for Sustainability

By proactively structuring its preclinical portfolio with various innovation profiles, including FIC, BIC, and Fast-Follow programs, Henlius has developed a tiered framework that balances pioneering innovation, development efficiency, and risk management. This approach ensures the continuous evolution of its innovation pipeline while establishing a sustainable and replicable growth model for globalization.

In conclusion, Henlius is set to shape the future of healthcare with its 'Globalisation 2.0' strategy, aiming for innovation that extends beyond borders, setting a new benchmark in the biopharmaceutical industry. The detailed planning and commitment to breakthrough therapies reflect the company's dedication to advancing healthcare solutions globally.